WEKO3
アイテム
{"_buckets": {"deposit": "afdb033c-f519-4755-b720-4821733d45b0"}, "_deposit": {"created_by": 1, "id": "66693", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "66693"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00066693", "sets": ["29"]}, "author_link": ["655834", "655819", "655830", "655814", "655832", "655827", "655823", "655833", "655816", "655821", "655822", "655815", "655813", "655820", "655818", "655828", "655824", "655825", "655831", "655826", "655817", "655829"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2016-06-14", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Beta-emitting meta-131I-iodo-benzylguanidine (MIBG) has been used in the treatment of malignant pheochromocytoma (PHEO). However the effects of MIBG and 5-year survival are limited. Alpha-emitters strongly suppress the growth of tumor cells. 211Astatine (211At) is an α-emitting halogen and has a suitable half-life for cancer therapy (t1/2=7.2 h). Therefore, meta-211At-astatobenzylguanidine (MABG) may potentially suppress the growth of malignant PHEO. In this study, we synthesized MABG and investigate the therapeutic effects of MABG in a rat PHEO model. 211At was produced via the 209Bi(α,2n)211At reaction and was isolated through dry distillation. MABG was synthesized by astatination of meta-trimethylsilylbenzylguanidine hemisulfate. MABG was highly taken up into a rat PHEO cell line, PC-12, through the norepinephrine transporter, and significantly suppressed clonogenic growth. DNA damage and cell cycle arrest at the G2/M phase were observed after MABG treatment. Biodistribution and therapeutic effects were examined using mice bearing PC-12. MABG was highly distributed and was retained in tumors. Furthermore, the tumor size was significantly reduced by the single administration of MABG (555 kBq/head) without an associated weight reduction. These results suggest that MABG might be an attractive therapeutic agent for the treatment of malignant PHEO.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "大島, 康宏"}], "nameIdentifiers": [{"nameIdentifier": "655813", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "渡辺, 茂樹"}], "nameIdentifiers": [{"nameIdentifier": "655814", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻, 厚至"}], "nameIdentifiers": [{"nameIdentifier": "655815", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "永津, 弘太郎"}], "nameIdentifiers": [{"nameIdentifier": "655816", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "坂下, 哲哉"}], "nameIdentifiers": [{"nameIdentifier": "655817", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "杉山, 僚"}], "nameIdentifiers": [{"nameIdentifier": "655818", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "原田, 良信"}], "nameIdentifiers": [{"nameIdentifier": "655819", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "脇, 厚生"}], "nameIdentifiers": [{"nameIdentifier": "655820", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "吉永, 恵一郎"}], "nameIdentifiers": [{"nameIdentifier": "655821", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "東, 達也"}], "nameIdentifiers": [{"nameIdentifier": "655822", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "石岡, 典子"}], "nameIdentifiers": [{"nameIdentifier": "655823", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "大島 康宏", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "655824", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "渡辺 茂樹", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "655825", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻 厚至", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "655826", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "永津 弘太郎", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "655827", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "坂下 哲哉", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "655828", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "杉山 僚", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "655829", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "原田 良信", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "655830", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "脇 厚生", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "655831", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "吉永 恵一郎", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "655832", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "東 達也", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "655833", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "石岡 典子", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "655834", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Therapeutic efficacy of α-emitter meta-211At-astato-benzylguanidine (MABG) in a pheochromocytoma model", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Therapeutic efficacy of α-emitter meta-211At-astato-benzylguanidine (MABG) in a pheochromocytoma model"}]}, "item_type_id": "10005", "owner": "1", "path": ["29"], "permalink_uri": "https://repo.qst.go.jp/records/66693", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-03-26"}, "publish_date": "2018-03-26", "publish_status": "0", "recid": "66693", "relation": {}, "relation_version_is_last": true, "title": ["Therapeutic efficacy of α-emitter meta-211At-astato-benzylguanidine (MABG) in a pheochromocytoma model"], "weko_shared_id": -1}
Therapeutic efficacy of α-emitter meta-211At-astato-benzylguanidine (MABG) in a pheochromocytoma model
https://repo.qst.go.jp/records/66693
https://repo.qst.go.jp/records/66693f79e9cb6-7c7f-4d69-bb99-cbfd6c3b01d2
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-03-26 | |||||
タイトル | ||||||
タイトル | Therapeutic efficacy of α-emitter meta-211At-astato-benzylguanidine (MABG) in a pheochromocytoma model | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
大島, 康宏
× 大島, 康宏× 渡辺, 茂樹× 辻, 厚至× 永津, 弘太郎× 坂下, 哲哉× 杉山, 僚× 原田, 良信× 脇, 厚生× 吉永, 恵一郎× 東, 達也× 石岡, 典子× 大島 康宏× 渡辺 茂樹× 辻 厚至× 永津 弘太郎× 坂下 哲哉× 杉山 僚× 原田 良信× 脇 厚生× 吉永 恵一郎× 東 達也× 石岡 典子 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Beta-emitting meta-131I-iodo-benzylguanidine (MIBG) has been used in the treatment of malignant pheochromocytoma (PHEO). However the effects of MIBG and 5-year survival are limited. Alpha-emitters strongly suppress the growth of tumor cells. 211Astatine (211At) is an α-emitting halogen and has a suitable half-life for cancer therapy (t1/2=7.2 h). Therefore, meta-211At-astatobenzylguanidine (MABG) may potentially suppress the growth of malignant PHEO. In this study, we synthesized MABG and investigate the therapeutic effects of MABG in a rat PHEO model. 211At was produced via the 209Bi(α,2n)211At reaction and was isolated through dry distillation. MABG was synthesized by astatination of meta-trimethylsilylbenzylguanidine hemisulfate. MABG was highly taken up into a rat PHEO cell line, PC-12, through the norepinephrine transporter, and significantly suppressed clonogenic growth. DNA damage and cell cycle arrest at the G2/M phase were observed after MABG treatment. Biodistribution and therapeutic effects were examined using mice bearing PC-12. MABG was highly distributed and was retained in tumors. Furthermore, the tumor size was significantly reduced by the single administration of MABG (555 kBq/head) without an associated weight reduction. These results suggest that MABG might be an attractive therapeutic agent for the treatment of malignant PHEO. | |||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting | |||||
発表年月日 | ||||||
日付 | 2016-06-14 | |||||
日付タイプ | Issued |